Cargando…
Role of Cognitive Enhancer Therapy in Alzheimer’s Disease with Concomitant Cerebral White Matter Disease: Findings from a Long-Term Naturalistic Study
BACKGROUND: Evidence is lacking for cognitive enhancer therapy in patients with Alzheimer’s disease (AD) and concomitant cerebrovascular disease (mixed AD) as such patients would have been excluded from clinical trials. Earlier studies of mixed AD have focused on large vessel cerebrovascular disease...
Autores principales: | Ng, Kok Pin, Ng, Aloysius, Assam, Pryseley, Heng, Esther, Kandiah, Nagaendran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153975/ https://www.ncbi.nlm.nih.gov/pubmed/25063270 http://dx.doi.org/10.1007/s40268-014-0057-5 |
Ejemplares similares
-
The Efficacy of Transdermal Rivastigmine in Mild to Moderate Alzheimer’s Disease with Concomitant Small Vessel Cerebrovascular Disease: Findings from an Open-Label Study
por: Yatawara, Chathuri, et al.
Publicado: (2021) -
Association between white matter hyperintensity load and grey matter atrophy in mild cognitive impairment is not unidirectional
por: Vipin, Ashwati, et al.
Publicado: (2021) -
APOE4 carrier status determines association between white matter disease and grey matter atrophy in early-stage dementia
por: Vipin, Ashwati, et al.
Publicado: (2023) -
Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer’s disease and cognitively unimpaired individuals
por: Ng, Kok Pin, et al.
Publicado: (2021) -
Chronic cerebral hypoperfusion enhances Tau hyperphosphorylation and reduces autophagy in Alzheimer’s disease mice
por: Qiu, Lifeng, et al.
Publicado: (2016)